FY2025 EPS Estimates for Liquidia Raised by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Liquidia in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.64) for the year, up from their previous estimate of ($0.94). The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q4 2025 earnings at $0.33 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $2.89 EPS, FY2027 earnings at $2.97 EPS, FY2028 earnings at $4.97 EPS and FY2029 earnings at $7.57 EPS.

LQDA has been the subject of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price objective on shares of Liquidia in a research report on Wednesday, February 25th. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. Jefferies Financial Group lifted their target price on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Finally, Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.67.

Liquidia Trading Up 8.2%

Shares of NASDAQ:LQDA opened at $34.38 on Thursday. Liquidia has a 52 week low of $11.26 and a 52 week high of $46.67. The company’s 50 day moving average is $37.09 and its two-hundred day moving average is $30.81. The company has a market cap of $2.99 billion, a PE ratio of -23.87, a P/E/G ratio of 0.92 and a beta of 0.52. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $92.02 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Farallon Capital Management LLC boosted its position in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC purchased a new stake in shares of Liquidia in the third quarter valued at about $38,887,000. Caprock Group LLC purchased a new stake in shares of Liquidia in the third quarter valued at about $37,114,000. Tyro Capital Management LLC acquired a new stake in shares of Liquidia in the second quarter valued at approximately $15,473,000. Finally, MPM Bioimpact LLC increased its stake in shares of Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after purchasing an additional 1,200,869 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Buying and Selling at Liquidia

In related news, insider Rajeev Saggar sold 21,142 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $791,345.06. Following the sale, the insider owned 176,883 shares in the company, valued at $6,620,730.69. This represents a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Dana Boyle sold 1,580 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $65,807.00. Following the completion of the transaction, the chief accounting officer directly owned 178,848 shares of the company’s stock, valued at $7,449,019.20. The trade was a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 212,534 shares of company stock worth $7,964,719. Corporate insiders own 26.50% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported YUTREPIA net product sales of $148.3M for full‑year 2025, $90.1M in Q4, achieved a second consecutive profitable quarter (Q4 net income $14.6M), and ended 2025 with $190.7M cash — supports revenue growth, near‑term profitability and funding for commercialization and trials. GlobeNewswire Release
• Positive Sentiment: HC Wainwright raised earnings estimates sharply across 2026–2029 (e.g., FY2026 to $2.89/sh and FY2029 to $7.57/sh) and issued quarter‑level upside forecasts — analyst model upgrades can drive buy interest and lift sentiment. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: HC Wainwright also published a long‑range FY2030 projection ($9.85/sh) — bullish but highly model‑sensitive and dependent on sustained commercial execution and trial outcomes. HC Wainwright longer‑term note (MarketBeat)
• Negative Sentiment: Despite Q4 profitability, Liquidia reported a 2025 net loss of $68.9M and SG&A rose 93% year‑over‑year — investors should watch margin trends as the company scales the commercial organization. Financial results (GlobeNewswire)
• Negative Sentiment: Recent SEC/filing reports show an investment manager sold ~$5.1M of LQDA shares and Quiver/press summaries highlight multiple insider and large institutional reductions — selling pressure and governance questions can cap near‑term upside. Fool: $5.1M institutional sale Quiver: insider & institutional trading summary

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).